Add to ORKGgeneral study on compliance conditions throughout a meta-analysis of 4354 patients treated with acamprosate in the aim of enhancement of abstinence. Very poor compliance was observed, and in the same time, essential main and interaction effect of compliance on the patient outcome.Etude générale des conditions d'observance à travers une méta-analyse de 4354 patients traités par acamprosate dans l'alcoolisme dépendant. Mise en evidence d'une tres faible observance, et paradoxalement, d'une importance considérable de l'observance dans le devenir du patient
This research was funded by Investigator Sponsored Trial (ISTBAL26102012) provided by Merck Serono L...
AimThe current research aims to systematically review the rates of adherence reported in randomised ...
Meta-analysis based on an international open label prospective study has shown that abstinence durin...
Method: Randomized parallel groups prospective trial to assess the efficacy of nursing follow up of...
Acamprosate was shown to help to maintain abstinence on alcoholic patients. In this paper, we show t...
Background: The aim of this study is to assess the influence of early and late compliance of acampro...
Initial severity of the patient before clinical trial is considered as the main predictor of therapy...
An assessment of the efficacy of treatment with acamprosate was, therefore, undertaken using meta-an...
Naturalistic randomised study controlled against any other treatment to assess the effect of acampro...
Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A ...
To assess the effectiveness of pharmacotherapy with acamprosate in alcohol-dependent patients treate...
Treatment with acamprosate is a valid tool to complement psychotherapy as it does not cause addictio...
We compared effects of the standard 2 g dose (n=258) and an exploratory 3 g dose of acamprosate (n=8...
Impact of active follow-up on abstinence in alcohol-dependent patients treated with acamprosate. Res...
ARES is the first naturalistic study to assess the effect of a pharmacological agent in alcoholism: ...
This research was funded by Investigator Sponsored Trial (ISTBAL26102012) provided by Merck Serono L...
AimThe current research aims to systematically review the rates of adherence reported in randomised ...
Meta-analysis based on an international open label prospective study has shown that abstinence durin...
Method: Randomized parallel groups prospective trial to assess the efficacy of nursing follow up of...
Acamprosate was shown to help to maintain abstinence on alcoholic patients. In this paper, we show t...
Background: The aim of this study is to assess the influence of early and late compliance of acampro...
Initial severity of the patient before clinical trial is considered as the main predictor of therapy...
An assessment of the efficacy of treatment with acamprosate was, therefore, undertaken using meta-an...
Naturalistic randomised study controlled against any other treatment to assess the effect of acampro...
Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A ...
To assess the effectiveness of pharmacotherapy with acamprosate in alcohol-dependent patients treate...
Treatment with acamprosate is a valid tool to complement psychotherapy as it does not cause addictio...
We compared effects of the standard 2 g dose (n=258) and an exploratory 3 g dose of acamprosate (n=8...
Impact of active follow-up on abstinence in alcohol-dependent patients treated with acamprosate. Res...
ARES is the first naturalistic study to assess the effect of a pharmacological agent in alcoholism: ...
This research was funded by Investigator Sponsored Trial (ISTBAL26102012) provided by Merck Serono L...
AimThe current research aims to systematically review the rates of adherence reported in randomised ...
Meta-analysis based on an international open label prospective study has shown that abstinence durin...